IL18 and pulmonary fibrosis: Nevertheless, the scutellarin treatment dose-dependently reduced the production of inflammatory cytokines IL-1β and IL-18 (Supplementary Fig. 3E, F), suggesting that the scutellarin could deliver anti-inflammatory function in pulmonary fibrosis in vitro and NF-κB/NLRP3 pathway might participate in this regulation process.